Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

Phase 4

Completed

• Conditions: Parkinson's Disease; Psychoses
• Interventions: Drug: aripiprazole

• Registration Number: NCT00095810
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The purpose of this clinical research study is to assess the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-07
• Primary Completion: 2004-09
• Study Completion: 2004-09
• Study First Submitted QC: 2004-11-08
• Study First Submitted: 2004-11-09
• Study First Posted: 2004-11-09
• Status Verified: 2010-12
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Primary diagnosis of idiopathic Parkinson's disease.
• Psychosis related to Parkinson's disease.

Exclusion Criteria

• Psychosis present prior to diagnosis of Parkinson's disease.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A	aripiprazole	-

Primary Outcome Measures

Name	Time	Method
Tolerability

Secondary Outcome Measures

Name	Time	Method
Safety Assessments

Trial Locations

Locations (1)

Local Institution; 🇺🇸 Albany, New York, United States